WSJ What’s News
What’s News in Markets: Chip Stocks Clobbered, Retail Rotation, Moderna Makes History
· Summarized
Key takeaways
- Rising bond yields are impacting the stock market, especially sectors with heavy borrowing needs like AI infrastructure.
- While consumers remain spending, they are becoming more selective, prioritizing bargains and delaying larger purchases.
- In healthcare, advancements in personalized mRNA cancer treatments could revolutionize oncology and boost biotech stocks.
- Market movement this week highlights the importance of monitoring macroeconomic factors such as debt levels and inflation.
Summary
Market Overview and Bond Market Dynamics
The week saw a generally subdued stock market, with major indexes declining due to rising oil prices and bond market turbulence. Key factors influencing the markets included the U.S. national debt surpassing $40 trillion, ongoing Middle Eastern conflicts affecting energy prices, and investors demanding higher returns for long-term bonds. Despite efforts by Treasury Secretary Scott Bessent to control borrowing costs, bond yields remained high, affecting equities and sectors linked to borrowing, notably AI infrastructure and semiconductors. The AI sector, heavily invested in by tech giants with off-balance sheet commitments, faced significant sell-offs, as higher interest rates made financing more expensive.
Consumer Behavior and Retail Insights
Retail sector performance hinted at cautious consumer spending amidst inflation and rising gas prices. Discount retailers like Ross and BJ's experienced gains as shoppers looked for bargains, with Ross's sales jumping 10%. However, some categories, especially larger purchases like home improvements, showed signs of hesitation. Walmart noted that lower-income consumers were making tough choices, impacting the broader economic outlook, while retailers like Home Depot and Lowe's are expected to provide further insight into retail trends.
Healthcare Sector and Moderna's Breakthrough
The healthcare sector emerged as a standout performer, highlighted by Moderna's soaring 177% shares after announcing a successful late-stage trial for a personalized mRNA cancer vaccine targeting melanoma. This marks a significant milestone, showcasing the potential of mRNA technology beyond COVID-19 vaccines. Merck also saw record highs, reflecting investor confidence in future cancer therapies. The positive developments propelled the biotech sector, with Moderna and Merck's stocks rising substantially, underscoring the promising future of personalized medicine in oncology.
Sponsors
- Fisher Investments · Thinking all wealth managers are the same? Fisher Investments is clearly different. As a fiduciary, they always do what's best for clients. They don't sell commission-based products or make commissions on trades. Their fees are structured so they do better when clients do better.
Show notes
What does mayhem in the bond market have to do with AI? And why are discount retailers getting a boost? Plus, how did Moderna help lift healthcare stocks? Host Imani Moise discusses the biggest stock moves of the week and the news that drove them.
Sign up for the WSJ's free Markets A.M. newsletter.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Follow this show on AudioBrevity and new episodes get summarized for you. Create a free account